Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
NTHI Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Neonc Technologies Holdings, Inc.
Market Cap
$77.54M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.07M
Return on Equity (ROE)
-1542.57%
TTM Avg
-254.55%
3Y Avg
-187.52%
5Y Avg
-143.69%
Market Cap
$78.29M
Return on Equity (ROE)
-55.97%
TTM Avg
-55.58%
3Y Avg
-51.87%
5Y Avg
-151.31%
Market Cap
$76.74M
Return on Equity (ROE)
-77.12%
TTM Avg
-270.75%
3Y Avg
-187.09%
5Y Avg
-136.77%
Market Cap
$78.59M
Return on Equity (ROE)
-6.05%
TTM Avg
-96.60%
3Y Avg
16.82%
5Y Avg
35.21%
Market Cap
$79.03M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$75.95M
Return on Equity (ROE)
-51.09%
TTM Avg
-35.88%
3Y Avg
-53.46%
5Y Avg
-40.30%
Market Cap
$79.61M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$75.18M
Return on Equity (ROE)
-122.76%
TTM Avg
-82.75%
3Y Avg
-63.80%
5Y Avg
-49.10%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | $77.54M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -1542.57% | -254.55% | -187.52% | -143.69% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -55.97% | -55.58% | -51.87% | -151.31% |
| Outset Medical, Inc. (OM)vs › | $76.74M | -77.12% | -270.75% | -187.09% | -136.77% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | -6.05% | -96.60% | 16.82% | 35.21% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | -114.06% | -50.52% | -45.18% | -45.18% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | -51.09% | -35.88% | -53.46% | -40.30% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -85.65% | -57.41% | -45.73% | -8.61% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -122.76% | -82.75% | -63.80% | -49.10% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -309.44% | -515.53% | -464.77% | -329.14% |
ROE
N/A
ROA
-902.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 354.96% |
